Kornimate/medical-research-clean huggingface dataset:
neuroprotective effects of hypothermia combined with inhaled xenon following perinatal asphyxia

Conditions: Hypoxic Ischaemic Encephalopathy

Summary: this is a randomised controlled trial in newborn infants with perinatal asphyxial encephalopathy assessing whether a combination of hypothermia and inhaled xenon preserve cerebral metabolism and structure.

the study hypothesis is that: following perinatal asphyxia treatment with a combination of hypothermia and inhaled xenon preserves cerebral metabolism and structure. following informed parental consent, infants that continue to require endotracheal tube ventilation following resuscitation will be randomised to treatment with hypothermia only or hypothermia and xenon. all infants in both groups will be treated with hypothermia for 72 hours started within 6 hours of delivery and infants allocated to hypothermia and xenon will also receive 30% xenon (balanced with oxygen and air) for 24 hours through a purpose designed delivery system. structured neurological examination will be done daily during the 1st week after birth and at discharge. mrs and mri will be performed once between 4-10 days of age. mrs/mri data analysis will be by investigators blinded to the allocated intervention.

Eligibility criteria:
inclusion criteria: infants will be eligible for enrolment into the trial if each of the following criteria is fulfilled: * infants 36 to 43 weeks gestation with at least one of the following: * apgar score of \<5 at 10 minutes after birth; * continued need for resuscitation, including endotracheal or mask ventilation, at 10 minutes after birth; * acidosis defined as ph \ 15 mmol/l in umbilical cord blood sample or any blood sample within 60 minutes of birth (arterial or venous blood). * moderate to severe encephalopathy consisting of altered state of consciousness (reduced or absent response to stimulation) and hypotonia, and abnormal primitive reflexes (weak or absent suck or moro response). clinical severity of hie will be assessed by thompson encephalopathy score, and modified sarnat score. * at least 30 minutes duration of amplitude integrated eeg (aeeg) recording that shows moderately abnormal or suppressed background aeeg activity or seizures exclusion criteria: * if treatment with hypothermia is delayed beyond 6 hours, or infants are expected to be \>12 hours of age at the time of randomisation; infants with ventilatory oxygen requirement \> 70%; attending clinician considers infant not suitable to participate because of other serious congenital abnormalities, or the infant's condition appears terminal.

Keywords: perinatal asphyxia encephalopathy neuroprotection
evaluation of vascular regeneration after a drug eluting stent implantation

Conditions: Stable Angina

Summary: this is a prospective cohort, one center. twenty patients who will undergo percutaneous stent implantation with everolimus eluting stent will be include. the primary endpoint was the correlation between the change (baseline vs. 1 week) in the number of circulating endothelial progenitor cells and in cell functionality following an everolimus eluting stent implantation with the grade of neointimal hyperplasia measured by optical coherence tomography

for the purpose of the study, flow cytometry analyses will be performed before intervention, at 1 week, 1 month and 9 months. in addition, cell functionality analyses will be performed by quantification of colony forming units, aldehidrodehidrogenase activity, cell proliferation by wst-1 and senescence by !-galactosidase enzyme. at 9 months the degree of neointimal proliferation will be measured by optical coherence tomography . a clinical follow-up will be performed at 1 year. secondary endpoints include: 1. to correlate the change in the number and cell functionality of circulation progenitor cells following everolimus eluting stent and the injury score analyses measured by optical coherence tomography, and the percentage of non covered struts by optical coherence tomography at 9 months. 2.-. to evaluate the role of other subtypes of cells cd 133+/kinase insert domain receptor (kdr+), cd 14+, mesenchymal stem cells, endothelial cell markers (ve cadherina, p1h12), integrin expression of macrophage-1 antigen (mac-1) and the development of neointimal hyperplasia.

Eligibility criteria:
inclusion criteria: * patients who present stable angina, silent ischemia or unstable angina whenever there is no elevation of markers of myocardial damage above the limit of normality * presence of at least one severe coronary stenosis (\> 70% by visual analysis), susceptible of percutaneous treatment with stent implantation and an optical coherence tomography study * all patients should be taking statins at least 2 months prior to their inclusion in the study. exclusion criteria: * age under 18 years and pregnant or fertile age, * patients with st-elevation myocardial infarction or non-st-elevation acute coronary syndrome with markers of recent myocardial damage (\<3 months), * patients in whom a drug-eluting stent and a bare stent have been implanted in the same procedure. * percutaneous treatment of restenotic lesions or total chronic occlusions. * the use of stent pre-implantation ablation techniques (rotablator, directional atherectomy). * chronic renal insufficiency with serum creatinine greater than or equal to 2.5. * coronary revascularization in previous 3 months. * severe ventricular dysfunction (\<25%). * major trauma or surgery in the previous 3 months. * previous organ transplantation, active neoplastic process or inflammatory disease, treatment with immunosuppressors. * contraindication or allergy to thienopyridines. * life expectancy less than one year.
clinical trial of the treatment of acute sinusitis with standard-dose versus high-dose amoxicillin/clavulanate

Conditions: Sinusitis

Summary: the aim is to determine if high-dose amoxicillin/clavulanate is more effective than standard-dose amoxicillin/clavulanate in treating acute bacterial sinusitis in adults seen at a primary care office.

the aim was amended in february 2016--because of the unexpected unavailability of the original high-dose formulation of amoxicillin/clavulanate--to compare the effectiveness (versus standard dose) of extended-release (the original formulation) versus immediate-release amoxicillin/clavulanate.

Eligibility criteria:
inclusion criteria: 1. adult 18 or over 2. meets definition of acute sinusitis by infectious disease society of america (2012) 3. clinician and participant chose to start antibiotic treatment exclusion criteria: 1. previously enrolled in the study 2. allergic or intolerant to amoxicillin, penicillin, or amoxicillin/clavulanate 3. specific medication concerns: lactating (since safety of clavulanate unknown); taking allopurinol (increased risk of rash); concurrent mononucleosis (increased risk of rash with amoxicillin); chronic kidney disease with glomerular filtration rate \< 30; significant hepatic impairment; history of antibiotic-associated colitis 4. cognitive impairment so that unable to give informed consent or give reliable assessment of improvement 5. need to use high-dose amoxicillin/clavulanate: treatment with amoxicllin or penicillin within the past month (risk of penicillin-resistant pneumococci), very ill patient (though not ill enough to send to hospital); immunocompromise 6. need to hospitalize the patient

Keywords: acute sinusitis amoxicillin/clavulanate adults outcomes
delirium in children undergoing stem cell transplantation

Conditions: Stem Cell Transplant Complications; Delirium

Summary: children undergoing stem cell transplants are at risk for delirium, a temporary change in thinking and behavior. this study will define delirium rates, risk factors, and outcomes. our eventual goal is to reduce delirium in this population.

delirium -- defined as an acute change in awareness and cognition that occurs in the setting of an underlying illness -- is a common complication of hematopoietic stem cell transplantation (hsct) in adults, with associated morbidity and mortality. this has never been studied in children, where risk factors may vary substantially from adults. the objectives of this study are: to define the epidemiology of delirium, and measure its effect on outcomes. this prospective longitudinal cohort study will prospectively establish the incidence of delirium in 1000 children in the peri-transplant period, and identify modifiable risk factors that predispose to delirium development. this study will also define the effect of delirium on important clinical outcomes, including neurocognitive function. this study will be executed by a research consortium of five leading pediatric oncologic transplant centers in north america, in collaboration with the leading pediatric delirium research group in the united states. this innovative proposal will leverage the combined experience of the pediatric delirium and hsct teams to expand urgently needed delirium research into a unique and unstudied population. by reducing delirium rates, outcomes after pediatric hsct can be optimized.

Eligibility criteria:
inclusion criteria: * age 0-21 years old * admitted for purpose of stem cell transplant exclusion criteria: * age \>21 years old * admitted for reason other than stem cell transplant (example: late post-transplant complications).

Keywords: pediatric stem cell transplant outcomes epidemiology
customer outcomes & value experiencing a new monitoring technology

Conditions: Diabetes Mellitus

Summary: to investigate whether novel insight features in new blood glucose monitoring system (bgms) can improve glycemic control.


Eligibility criteria:
inclusion criteria summary: * diagnosed with type 1 diabetes mellitus or type 2 diabetes mellitus for ≥ 3 month prior to screening * currently performing self-monitoring of blood glucose (smbg) at home for diabetes management decisions * willingness to notify the study staff if they become pregnant during the study * willing to sign an informed consent exclusion criteria summary: * currently using a continuous or flash glucose monitoring * currently pregnant or planning pregnancy within duration of study or breast feeding; subjects who become pregnant during the study will be withdrawn. * conflict of interest
postoperative cognitive dysfunction in geriatric patients

Conditions: Delirium, Dementia, Amnestic, Cognitive Disorders; Postoperative Complications; Memory Disorders

Summary: geriatric patients have a high risk of developing postoperative cognitive deficits. hypothetical causes are insufficient intraoperative cerebral perfusion or drugs that are administered in the perioperative setting. this study will investigate the role of these two factors in patients aged 65 or older undergoing elective surgical procedures under general aesthesia. non-invasive techniques will be used to monitor intraoperative cerebral perfusion and anticholinergic activity in the patient's blood is determined. data will be compared to those of a young (20-40 year old) group of patients undergoing elective surgical procedures using an identical anesthetic technique. a second control group of healthy volunteers older than 65 will be investigated to quantify practice effects with repeated testing of cognitive functions.


Eligibility criteria:
inclusion criteria: * elective surgical procedure under general anaesthesia exclusion criteria: * history of cerebrovascular disease * mini mental status \<23 * cardiac surgery * neurosurgery
utility of at-home monitoring of exercise capacity by app-based 6-minute walk test

Conditions: Pulmonary Arterial Hypertension

Summary: * evaluate for accuracy and reproducibility of data collected via the participant-operated walk.talk.track. (wtt) app combined with apple watch during in-clinic, technician proctored 6mwt's. * determine whether the wtt app on the apple watch can accurately collect information on distance traveled and heart rate (hr) during in-clinic 6mwt run by american thoracic society (ats) guidelines * determine whether participants can operate the wtt app and apple watch effectively to gather accurate data in a monitored and home-based setting * prospectively monitor for changes in wtt app recorded 6mwt results following initiation of therapy in a treatment naïve cohort of pah participants * evaluate whether changes from baseline in 6 minute walk distance (6mwd) and heart rate recovery at one minute (hrr1) as well as other variables that have been associated with disease severity in pah and left-sided heart disease (resting hr, heart rate variability \[hrv\], chronotropic index \[ci\]) can be identified before the 12-week follow up when comparing the treatment arm and the control arm * evaluate whether changes from baseline in the hrr1, resting hr, hrv and/or ci are more evident in treatment responders when compared to treatment non-responders.


Eligibility criteria:
inclusion criteria: * diagnosis of who group i pulmonary arterial hypertension (pah) (idiopathic (i)pah, heritable pah (including hereditary hemorrhagic telangiectasia), associated (a)pah (including collagen vascular disorders, drugs+toxins exposure, congenital heart disease, and portopulmonary disease). * do not meet exclusion criteria exclusion criteria: * pulmonary hypertension due to left heart disease (ph-lhd, who group 2), pulmonary hypertension due to chronic lung disease (ph-cld, who group 3), chronic thrombo-embolic pulmonary hypertension (cteph, who group 4), pulmonary hypertension with unclear and/or multi-factorial mechanisms (who goup 5) * inability to perform a 6 minute walk test (6mwt)

Keywords: six minute walk test six minute walk distance heart rate recovery mobile health
ct-angiographic follow up of patients that underwent coronary bypass surgery between 1993-1997

Conditions: Coronary Artery Disease

Summary: coronary artery surgery (cabg) is necessary to improve blood circulation in many patients with coronary artery disease. this is done by using alternative blood vessels (grafts) to bypass the stenosed coronary arteries. in cabg, vein grafts are traditionally used where surrounding tissue is removed, this may damage the vessel and influence its patency. the "no-touch" technique was developed by professor domingos souza at the department of cardiovascular and thoracic surgery, örebro university hospital. this technique includes taking out the vein with its surrounding tissue and by this way the vessel is less damaged. the first two follow ups have shown that no-touch grafts had better patency than conventionally extracted graft at 18 months and 8.5 years. this long term follow up is a continuation of the randomized trial started in 1993 where the patency and incidence of stenoses in the no touch and conventional vein grafts has been studied.


Eligibility criteria:
inclusion criteria: 1. first time coronary artery bypass grafting with either conventional or no touch vein grafts performed by dr.souza between 1993-1997. 2. included in the previous follow up studies 3. signed and dated consent. exclusion criteria: 1. allergy to contrast 2. renal failure 3. uncontrolled diabetes 4. unable to implement the study according to protocol -

Keywords: coronary artery bypass grafting saphenous vein grafts
an rct to compare early continence recovery after rarp with or without sustainable functional urethral reconstruction

Conditions: Prostate Cancer; Urinary Incontinence

Summary: the study is a prospective randomized controlled trail to compare early urinary continence recovery after robotic-assisted radical prostatectomy with or without sustainable functional urethral reconstruction (sfur).

early urinary incontinence has always been a tricky problem for both patients and urologists, even though over 90% patients can recover 1 year after surgery. many urologists are trying to modify the surgical technique to resolve this problem. sustainable functional urethral reconstruction (sfur) is a novel technique which may improve early urinary continence recovery for both local and locally advanced prostate cancer, and even for those with high volume prostate by providing adequate urethral length with bladder neck tubularization and making sustainable periurethral support with peritoneal flap. the purpose of this study is to verify the impact of this new technique on early recovery of urinary continence, as well as on urinary function and oncological outcomes.

Eligibility criteria:
inclusion criteria: * ≥40, but ≤75 years old； * histological confirmed prostate cancer； * localized or locally advanced prostate cancer； * presence of urinary continence prior to the procedure; * informed consent signed; exclusion criteria: * metastatic prostate cancer confirmed by ect, psma or whole-body mri; * presence of any prostatic surgery(such as transurethral resection, laser therapy, microwave therapy, radiofrequency ablation and so on) prior to the procedure; * radiation therapy of the prostate or pelvis prior to the procedure; * uncontrolled intercurrent illness that would limit compliance with study requirements; * any condition that contraindicates a radical prostatectomy;

Keywords: prostate cancer prostatectomy robotic surgery urinary incontinence sustainable functional urethral reconstruction
investigation of alzheimer's disease and periodontal status

Conditions: Alzheimer Disease; Periodontal Diseases

Summary: the aim of this study is to investigate the effect of the current periodontal status on the progression rate of ad.

although much is known about its pathogenesis, alzheimer's disease (ad) is still a terminal disease. for this reason, the correct evaluation and treatment of the risk factors of the disease gains importance in the prevention of the disease. chronic inflammation, such as periodontal disease, can speed up the onset and progression of ad. the study aimed to investigate the relationship between periodontal status and the rate of progression of dementia in individuals diagnosed with alzheimer's disease. in this study, 90 individuals with ad, who were classified as stage i, stage ii, and stage iii according to the clinical dementia rating scale. baseline and 6th month cognitive status assessments of participants who met the inclusion criteria were performed in the department of neurology using smmt. at the 6th month control appointment in the neurology department, the participants were referred to the periodontology department for oral examinations. in the periodontology department, dental anamnesis of the patients was taken and intraoral examinations were performed. periodontal examination of all existing teeth of all participants with at least one remaining tooth (excluding third molars) with a williams-marked periodontal probe (hu-friedy, chicago, illinois, usa) and all molars and maxillary first premolars with nabers probe (pq2n, hu-friedy, chicago, illinois, usa) was performed and records %p (plak percentage), %bop (percentage bleeding on probing), cal (clinical attachment level), ppd (probing pocket depth). the position of the gingival margin and ppd were measured at six sites/teeth (including/excluding third molars). the cal was then calculated from these measurements. in 2017, periodontal status was determined according to the decisions of the world workshop on periodontal and peri-implant diseases and classification of conditions. the current occlusal relationship status of all patients was evaluated using the eichner index and classified as type 1 (a1-a2-a3-b1) , type 2 (b2-b3) and type 3 (b4-c1-c2-c3).

Eligibility criteria:
inclusion criteria: * those who have been diagnosed with probable alzheimer's disease in the age range of 50-89 * do not have dementia other than alzheimer type dementia. * does not have a psychiatric disorder effecting cognitive status and does not use drugs that effect cognitive status. * those who have other existing systemic diseases (cardiovascular disease, diabetes) under control other than alzheimer's disease. * not using regular anti-inflammatory and corticosteroids * c-reactive protein (crp) value was measured within 6 months prior to the date of inclusion in the study. * non-smoker and no alcohol intake * have not received any dental treatment in the last 1 year * in those with less than 10 teeth, the edentulousness was prosthetically rehabilitated. exclusion criteria: -

Keywords: alzheimer's disease cognitive decline periodontal disease periodontitis occlusion chewing
the effectiveness and safety of niacinamide 4% and virgin coconut oil 30% for secondary prevention of occupational hand dermatitis

Conditions: Contact Dermatitis of Hands

Summary: occupational hand dermatitis (ohd) often occurs in intensive care unit (icu) nurses, especially in individuals who are vulnerable due to irritant exposure e.g. hand rub alcohol and repeated hand washing activities. the use of moisturizer is one of the recommendations for skin care in ohd. niacinamide which has anti-inflammatory effects and can improve the skin barrier function. virgin coconut oil (vco) is rich in lipids and lauric acid, and has an occlusive effect. until now there are no guidelines and reference types of moisturizers for secondary prevention in dtak.

the aim of this study is identify the effectiveness and safety between moisturizing cream containing niacinamide 4% and vco 30% for secondary prevention of occupational hand dermatitis in icu nurses this study also measured hecsi , tewl, and scap before and after treatment

Eligibility criteria:
inclusion criteria: icu nurses who: * sign the informed consent of the study after receiving explanation before all activity related with this study begin. * has occupation hand dermatitis that fulfill the mathias criteria with dermatitis severity mild to moderate which the score is 1, 2 or 3 corresponding with investigator global assesment (iga) * agree to follow the study protocol exclusion criteria: * history of allergic or irritate by niacinamide or vco or other component in moisturizer * receiving medium to high potency of topical corticosteroid or systemic immunosupresant therapy or history of oral corticosteroid therapy in the last 1 month

Keywords: occupational hand dermatitis moisturizer niacinamide virgin coconut oil hecsi tewl scap